309 lines
No EOL
38 KiB
XML
309 lines
No EOL
38 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK588652" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK588652/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Patisiran - LiverTox - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Patisiran" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2025/02/25" /><meta name="citation_pmid" content="36689610" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK588652/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Patisiran" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2025/02/25" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK588652/" /><meta name="description" content="Patisiran is a synthetic small interfering RNA (siRNA) molecule directed against the mRNA of transthyretin that is used to treat adults with the polyneuropathy of transthyretin-mediated amyloidosis. Patisiran has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent liver injury with symptoms or jaundice." /><meta name="og:title" content="Patisiran" /><meta name="og:type" content="book" /><meta name="og:description" content="Patisiran is a synthetic small interfering RNA (siRNA) molecule directed against the mRNA of transthyretin that is used to treat adults with the polyneuropathy of transthyretin-mediated amyloidosis. Patisiran has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent liver injury with symptoms or jaundice." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK588652/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Patisiran/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK588652/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DCC8D7D7E77B1000000000068004C.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK588652_"><span class="title" itemprop="name">Patisiran</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 25, 2025</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Patisiran.OVERVIEW"><h2 id="_Patisiran_OVERVIEW_">OVERVIEW</h2><div id="Patisiran.Introduction"><h3>Introduction</h3><p>Patisiran is a synthetic small interfering RNA (siRNA) molecule directed against the mRNA of transthyretin that is used to treat adults with the polyneuropathy of transthyretin-mediated amyloidosis. Patisiran has not been linked to serum aminotransferase elevations during therapy or to instances of clinically apparent liver injury with symptoms or jaundice.</p></div><div id="Patisiran.Background"><h3>Background</h3><p>Patisiran (pa” ti sir’ an) is a synthetic, double-stranded, small interfering RNA (siRNA) directed against the mRNA of transthyretin, a serum protein made in the liver whose major function is transport of vitamin A and thyroxine. Rare mutations in the transthyretin gene result in misfolding of the protein and accumulation of large amyloid deposits of transthyretin molecules most prominently in peripheral nerves and the heart. Patients with inherited transthyretin amyloidosis typically present with polyneuropathy or autonomic dysfunction followed by cardiomyopathy which, if untreated, is usually fatal within 5 to 12 years. Patisiran was developed to reduce production of transthyretin (both the wild type and mutant forms) and prevent accumulation of further amyloid deposits. Patisiran is administered intravenously, and uptake by the liver is facilitated by its packaging in lipid nanoparticles (which also protect against ribonuclease digestion). Once taken up by hepatocytes, the siRNA is cleaved into smaller fragments and separated into single strands that bind and silence the mRNA of transthyretin. In animal models, patisiran reduced transthyretin protein levels in blood and mRNA levels in liver. In trials of patisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy, intravenous infusions resulted in rapid and sustained reductions in serum transthyretin levels (averaging ~78%) and significant improvements in neuropathy and quality of life scales compared to placebo therapy. Patisiran was approved for use in the United States in 2018 for adults with transthyretin amyloidosis and polyneuropathy. It is under evaluation for efficacy and safety in patients with cardiomyopathy due to transthyretin amyloidosis. Patisiran is available in a lipid complex solution in single dose vials of 10 mg in 5 mL (2 mg/mL) under the brand name Onpattro. The recommended dose regimen is 0.3 mg/kg (to a maximal dose 30 mg) administered intravenously every 3 weeks. Administration by a health care provider is required as is premedication with corticosteroids, acetaminophen, antihistamines and an H2 blocker. Patisiran is generally well tolerated the most common side effects being injection site reactions. Other potential adverse events include peripheral edema, fatigue, arthralgias, diarrhea and musculoskeletal pains. In preregistration studies, 3% of patisiran treated patients developed anti-drug antibodies, but their presence was not associated with decreased efficacy or safety. Because patisiran reduces serum transthyretin levels, it also reduces serum vitamin A levels and vitamin A supplementation is recommended using doses of the recommended daily allowance.</p></div><div id="Patisiran.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In preregistration trials, patisiran therapy was well tolerated except for infusion reactions. Patients with amyloidosis often have hepatomegaly and mild serum enzyme elevations. Serum aminotransferase elevations arose in approximately 20% of patisiran- vs 10% of placebo-recipients, but the elevations were usually mild (less than 5 times ULN), transient and without accompanying symptoms or jaundice. Since its approval, there have been no published reports of liver injury attributed to patisiran therapy. Thus, patisiran is an unlikely cause of clinically apparent liver injury, although it has had limited widescale clinical use.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Patisiran.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The possible cause of hepatic injury from patisiran or other siRNA therapeutics is not known. Patisiran has been linked to mild-to-moderate, transient serum aminotransferase elevations that usually resolve spontaneously without dose modification. The cause of these abnormalities is unknown, but patients with amyloidosis can have hepatomegaly and minor serum enzyme elevations while on no therapy. Alternatively, the serum ALT and AST elevations may relate to the lipid complex used to improve hepatic update of the siRNA. Patisiran, like other RNA therapeutic agents, is metabolized intracellularly by nucleases and is not a substrate of cytochrome P450 enzymes or hepatic transporters.</p></div><div id="Patisiran.Outcome_and_Management"><h3>Outcome and Management</h3><p>Patisiran has not been linked to clinically significant liver test abnormalities or to clinically apparent liver injury and regular monitoring of routine liver tests is not recommended. The requirements for intravenous administration and premedication makes management of therapy challenging.</p><p>Drug Class: Genetic Disorder Agents, siRNA and Antisense Agents</p><p>Other Therapeutic siRNA-based Agents: <a href="/books/n/livertox/Givosiran/">Givosiran</a>, <a href="/books/n/livertox/Inclisiran/">Inclisiran</a>, <a href="/books/n/livertox/Lumasiran/">Lumasiran</a>, <a href="/books/n/livertox/Vutrisiran/">Vutrisiran</a></p><p>Other Drugs for Transthyretin-Mediated Amyloidosis: <a href="/books/n/livertox/Acoramidis/">Acoramidis</a>, <a href="/books/n/livertox/Eplontersen/">Eplontersen</a>, <a href="/books/n/livertox/Tafamidis/">Tafamidis</a>, <a href="/books/n/livertox/Vutrisiran/">Vutrisiran</a></p></div></div><div id="Patisiran.PRODUCT_INFORMATION"><h2 id="_Patisiran_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
||
<b>REPRESENTATIVE TRADE NAMES</b>
|
||
</p><p>Patisiran – Onpattro®</p><p>
|
||
<b>DRUG CLASS</b>
|
||
</p><p>Genetic Disorder Agents</p><p>
|
||
<a href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e87ec36f-b4b4-49d4-aea4-d4ffb09b0970" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
||
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Patisiran.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Patisiran_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Patisiran.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK588652/table/Patisiran.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Patisiran.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Patisiran.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Patisiran.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_Patisiran.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Patisiran.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Patisiran.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patisiran</td><td headers="hd_h_Patisiran.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/350082694" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">1420706-45-1</a>
|
||
</td><td headers="hd_h_Patisiran.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C412-H480-N148-Na40-O290-P40</td><td headers="hd_h_Patisiran.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not Available</td></tr></tbody></table></div></div></div><div id="Patisiran.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Patisiran_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 25 February 2025</p><p>Abbreviations: mRNA, messenger RNA; siRNA, small interfering RNA.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Patisiran.REF.patisiran.2018">FDA. Patisiran. Multi-Discipline Review. 2018.</div></li><li><div class="bk_ref" id="Patisiran.REF2">
|
||
<a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000MultiR.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>.accessdata<wbr style="display:inline-block"></wbr>.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>/nda/2018/210922Orig1s000MultiR<wbr style="display:inline-block"></wbr>.pdf</a>
|
||
|
||
<div>
|
||
<i>(The FDA clinical review of patisiran for efficacy and safety reported that ALT elevations arose in 20% of patisiran- vs 10% of placebo-recipients in preregistration controlled trials, but that all elevations were transient, less than 5 times the ULN, and were not associated with jaundice or symptoms; in addition, there were no hepatic serious adverse events or deaths).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Patisiran.REF.suhr.2015.109">Suhr
|
||
OB, Coelho
|
||
T, Buades
|
||
J, Pouget
|
||
J, Conceicao
|
||
I, Berk
|
||
J, Schmidt
|
||
H, et al.
|
||
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.
|
||
Orphanet J Rare Dis.
|
||
2015;10:109.
|
||
[<a href="/pmc/articles/PMC4559363/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4559363</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26338094" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26338094</span></a>]<div><i>(Among 29 patients with hereditary transthyretin amyloidosis with polyneuropathy treated with varying doses regimens of patisiran, there was a rapid marked decline in serum transthyretin levels [averaging -85%] and adverse events were mild-to-moderate, mostly infusion reactions, not requiring discontinuation, and “no clinically significant changes in liver function tests…were recorded”).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.butler.2016.109">Butler
|
||
JS, Chan
|
||
A, Costelha
|
||
S, Fishman
|
||
S, Willoughby
|
||
JL, Borland
|
||
TD, Milstein
|
||
S, et al.
|
||
Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.
|
||
Amyloid.
|
||
2016;23:109-18.
|
||
[<a href="/pmc/articles/PMC4898164/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4898164</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27033334" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27033334</span></a>]<div><i>(In a murine model of hereditary transthyretin-mediated amyloidosis, patisiran resulted in knock down of transthyretin and dose related regression of amyloid deposits).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.adams.2018.11">Adams
|
||
D, Gonzalez-Duarte
|
||
A, O'Riordan
|
||
WD, Yang
|
||
CC, Ueda
|
||
M, Kristen
|
||
AV, Tournev
|
||
I, et al.
|
||
Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.
|
||
N Engl J Med.
|
||
2018;379:11-21.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/29972753" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29972753</span></a>]<div><i>(Among 245 patients with hereditary transthyretin amyloidosis treated with patisiran [0.3 mg/kg] or placebo intravenously every 3 weeks for up to 6 months, neuropathy and quality of life scores improved with patisiran therapy and usually worsened with placebo, while adverse event rates were similar in the two groups except for infusion reactions [19% vs 9%] and peripheral edema [30% vs 22%], and there were no “clinically relevant changes in laboratory values” including indicators of liver function).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.hoy.2018.1625">Hoy
|
||
SM. Patisiran: first global approval.
|
||
Drugs.
|
||
2018
|
||
Oct;78(15):1625-1631.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/30251172" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30251172</span></a>]<div><i>(Review of the mechanism of action, structure, history of development, clinical efficacy and safety of patisiran shortly after its approval for use in hereditary transthyretin amyloidosis with polyneuropathy, mentions that there were no treatment related serious adverse events; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.setten.2019.421">Setten
|
||
RL, Rossi
|
||
JJ, Han
|
||
SP. The current state and future directions of RNAi-based therapeutics.
|
||
Nat Rev Drug Discov
|
||
2019; 18: 421-46.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/30846871" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30846871</span></a>]<div><i>(Extensive review of gene silencing using RNA interference pathways and the potential of RNAi therapeutics which have promise in many genetic and acquired diseases including transthyretin amyloidosis [transthyretin], HIV infection [CCR5], HBV [HBV mRNA], alpha-1-antitrypsin deficiency [zz A1AT], hypercholesterolemia [PCSK9]).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.zhang.2020.37">Zhang
|
||
X, Goel
|
||
V, Attarwala
|
||
H, Sweetser
|
||
MT, Clausen
|
||
VA, Robbie
|
||
GJ. Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the phase 3 APOLLO Trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
|
||
J Clin Pharmacol.
|
||
2020;60:37-49.
|
||
[<a href="/pmc/articles/PMC6972979/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6972979</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31322739" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31322739</span></a>]<div><i>(Pharmacokinetic studies conducted on 145 patients with hereditary transthyretin amyloidosis treated with patisiran for 18 months demonstrated stable drug levels and only 5 subjects developed anti-drug antibodies [3.4%] that had no appreciable effects on drug levels, efficacy or safety).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.coelho.2020.179">Coelho
|
||
T, Adams
|
||
D, Conceição
|
||
I, Waddington-Cruz
|
||
M, Schmidt
|
||
HH, Buades
|
||
J, Campistol
|
||
J, et al.
|
||
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
|
||
Orphanet J Rare Dis.
|
||
2020;15:179.
|
||
[<a href="/pmc/articles/PMC7341568/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7341568</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32641071" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32641071</span></a>]<div><i>(Among 27 patients with transthyretin amyloidosis participating in a phase 2 trial of patisiran which was then continued for 24 months, improvements in neuropathy and quality of life were sustained and adverse events were generally mild, with no discontinuations for adverse events and no significant changes in liver biochemical test results).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.adams.2021.49">Adams
|
||
D, Polydefkis
|
||
M, González-Duarte
|
||
A, Wixner
|
||
J, Kristen
|
||
AV, Schmidt
|
||
HH, Berk
|
||
JL, et al.; patisiran Global OLE study group. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
|
||
Lancet Neurol.
|
||
2021;20:49-59.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/33212063" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33212063</span></a>]<div><i>(Among 211 patients with hereditary transthyretin amyloidosis and polyneuropathy enrolled in an open label extension study after phase 2 and 3 controlled trials of patisiran, improvements in neuropathy and quality of life scores arose in placebo groups when crossed over to active therapy and were sustained in active treatment groups, and there were “no clinically relevant safety concerns…related to hepatic events”).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.luigetti.2021.21">Luigetti
|
||
M, Servidei
|
||
S. Patisiran in hereditary transthyretin-mediated amyloidosis.
|
||
Lancet Neurol.
|
||
2021;20:21-23.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/33212064" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33212064</span></a>]<div><i>(Editorial in response to Adams [2021] summarizing results on the efficacy of patisiran in hereditary transthyretin amyloidosis and discussing the uncertainty related to long term therapy and treatment of advanced disease and cardiomyopathy).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.suzuki.2021.100424">Suzuki
|
||
Y, Ishihara
|
||
H. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs.
|
||
Drug Metab Pharmacokinet.
|
||
2021;41:100424.
|
||
[<a href="/pmc/articles/PMC8502116/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8502116</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34757287" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34757287</span></a>]<div><i>(Description of the lipid components used to create nanoparticles for administration of patisiran, the lipids protecting the RNA against nuclease digestion and allowing uptake by hepatocytes [via the LDL receptor] and release of the siRNA with acidification of the endosomes containing the incorporated patisiran).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.schmidt.2022.1646">Schmidt
|
||
HH, Wixner
|
||
J, Planté-Bordeneuve
|
||
V, Muñoz-Beamud
|
||
F, Lladó
|
||
L, Gillmore
|
||
JD, Mazzeo
|
||
A, et al.; Patisiran Post-LT Study Group. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
|
||
Am J Transplant.
|
||
2022;22:1646-1657.
|
||
[<a href="/pmc/articles/PMC9310767/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9310767</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35213769" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35213769</span></a>]<div><i>(Among 12 patients with hereditary transthyretin amyloidosis with polyneuropathy who had undergone liver transplant but continued to have neuropathy were treated with patisiran for at least 12 months, neuropathy and autonomic syndrome scores improved while disability and nutrition status were stable; 11 [48%] patients developed ALT elevations that were usually transient and mild, one developed acute rejection and one cholangitis, but all abnormalities resolved despite continued patisiran therapy without dose modification).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.aimo.2022.655">Aimo
|
||
A, Castiglione
|
||
V, Rapezzi
|
||
C, Franzini
|
||
M, Panichella
|
||
G, Vergaro
|
||
G, Gillmore
|
||
J, et al.
|
||
RNA-targeting and gene editing therapies for transthyretin amyloidosis.
|
||
Nat Rev Cardiol.
|
||
2022;19(10):655-667.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/35322226" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35322226</span></a>]<div><i>(Extensive review of the molecular basis of hereditary transthyretin amyloidosis and the small molecule and RNA based therapies in current use and in experimental clinical trials, mentions the efficacy and relative safety of patisiran which has not been linked to instances of liver dysfunction).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.di_stefano.2022.499">Di Stefano
|
||
V, Fava
|
||
A, Gentile
|
||
L, Guaraldi
|
||
P, Leonardi
|
||
L, Poli
|
||
L, Tagliapietra
|
||
M, et al.
|
||
Italian real-life experience of patients with hereditary transthyretin amyloidosis treated with patisiran.
|
||
Pharmgenomics Pers Med.
|
||
2022;15:499-514.
|
||
[<a href="/pmc/articles/PMC9113125/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9113125</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35592550" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35592550</span></a>]<div><i>(Case histories of 9 patients with transthyretin amyloidosis with polyneuropathy who were treated long term with patisiran in “Italian real-life” with clinical improvement and excellent tolerance; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.maurer.2022.s23">Maurer
|
||
MS. Overview of current and emerging therapies for amyloid transthyretin cardiomyopathy.
|
||
Am J Cardiol.
|
||
2022;185
|
||
Suppl 1:S23-S34.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/36371281" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36371281</span></a>]<div><i>(Review of approaches to therapy of amyloid transthyretin cardiomyopathy including the transthyretin stabilizers [tafamidis, acoramidis] and transthyretin gene silencing or knockdown agents [patisiran, vutrisiran, inotersen, eplontersen, CRISPR-Cas9], no mention of liver related adverse events).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.ranasinghe.2023.2697">Ranasinghe
|
||
P, Addison
|
||
ML, Dear
|
||
JW, Webb
|
||
DJ. Small interfering RNA: Discovery, pharmacology and clinical development–An introductory review.
|
||
Br J Pharmacol.
|
||
2023;180(21):2697-2720.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/36250252" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36250252</span></a>]<div><i>(Review of the history of development, mechanism of action, methods of delivery, clinical efficacy and safety of RNA silencing drugs including lumasiran, givosiran, inclisiran, patisiran and vutrisiran, discusses adverse events from patisiran of injection site reactions, but does not mention hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.aimo.2022.655_1">Aimo
|
||
A, Castiglione
|
||
V, Rapezzi
|
||
C, Franzini
|
||
M, Panichella
|
||
G, Vergaro
|
||
G, Gillmore
|
||
J, et al.
|
||
RNA-targeting and gene editing therapies for transthyretin amyloidosis.
|
||
Nat Rev Cardiol.
|
||
2022;19:655-667.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/35322226" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35322226</span></a>]<div><i>(Review of the molecular approaches to therapy of transthyretin-related amyloidosis including small interfering RNA [siRNA, patisiran, vutrisiran], antisense RNA [inotersen, eplontersen], CRISPR-Cas9 therapy, and molecular stabilization agents [acoramidis, tafamidis], some of which been linked to minor serum aminotransferase elevations during therapy [vutrisiran, eplontersen], but not to clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.adams.2023.1">Adams
|
||
D, Tournev
|
||
IL, Taylor
|
||
MS, Coelho
|
||
T, Planté-Bordeneuve
|
||
V, Berk
|
||
JL, González-Duarte
|
||
A, et al.; HELIOS-A Collaborators. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
|
||
Amyloid.
|
||
2023;30:1-9.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/35875890" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35875890</span></a>]<div><i>(Among 164 patients with hereditary transthyretin amyloidosis with polyneuropathy treated with vutrisiran [25 mg subcutaneously every 3 months] or patisiran 0.3 mg/kg intravenously every 3 weeks] for 18 months, vutrisiran was found to be non-inferior to patisiran and more effective than placebo [from an external placebo group] and most adverse events were mild and there were no drug related discontinuations or deaths; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.maurer.2023.1553">Maurer
|
||
MS, Kale
|
||
P, Fontana
|
||
M, Berk
|
||
JL, Grogan
|
||
M, Gustafsson
|
||
F, Hung
|
||
RR, et al.; APOLLO-B Trial Investigators. Patisiran treatment in patients with transthyretin cardiac amyloidosis.
|
||
N Engl J Med.
|
||
2023;389(17):1553-1565.
|
||
[<a href="/pmc/articles/PMC10757426/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10757426</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37888916" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 37888916</span></a>]<div><i>(Among 360 patients with transthyretin-mediated amyloidosis and cardiomyopathy treated with patisiran [0.3 mg/kg] or placebo intravenously every 3 weeks for 12 months, decline in 6 minute walk distance was lower with patisiran and cardiomyopathy questionnaire scores improved more with patisiran; while adverse event rates were similar [91% vs 94%], those attributed to the drug were infusion reactions, arthralgia and muscle spasms, and “no clinically relevant changes in laboratory measures (including …liver-function tests…] were observed”).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.liu.2024.1368244">Liu
|
||
Y, Li
|
||
H, Hu
|
||
C, Tan
|
||
L, Yin
|
||
P, Li
|
||
Z, Zhou
|
||
S, Su
|
||
L.
|
||
A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database.
|
||
Front Pharmacol.
|
||
2024;15:1368244.
|
||
[<a href="/pmc/articles/PMC11169801/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11169801</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38873427" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38873427</span></a>]<div><i>(Analysis of the FDA Adverse Event Reporting System [FAES] reports on transthyretin inhibitors made over a 5 year period, found the top 50 events for patisiran included fatigue, asthenia, and falls, but not liver test abnormalities).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.ruberg.2024.778">Ruberg
|
||
FL, Maurer
|
||
MS. Cardiac amyloidosis due to transthyretin protein: a review.
|
||
JAMA. 2024;331:778-791.
|
||
[<a href="/pmc/articles/PMC11167454/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11167454</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38441582" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 38441582</span></a>]<div><i>(Review of the pathogenesis, genetics, clinical features, diagnosis, and treatment of transthyretin-mediated amyloidosis cardiomyopathy; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Patisiran.REF.adams.2025">Adams
|
||
D, Wixner
|
||
J, Polydefkis
|
||
M, Berk
|
||
JL, Conceição
|
||
IM, Dispenzieri
|
||
A, Peltier
|
||
A, et al.
|
||
Five-year results with patisiran for hereditary transthyretin amyloidosis with polyneuropathy: a randomized clinical trial with open-Label extension.
|
||
JAMA Neurol.
|
||
2025
|
||
Jan
|
||
13. Epub ahead of print.
|
||
[<a href="https://pubmed.ncbi.nlm.nih.gov/39804640" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 39804640</span></a>]<div><i>(Among 212 patients who completed the placebo controlled trial of patisiran for transthyretin amyloid polyneuropathy [Adams 2023] who were then enrolled in an open label extension study, polyneuropathy disability scores remained stable or improved, exposure adjusted survival rate was improved, and no new safety concerns were identified; no mention of ALT elevations or hepatotoxicity).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK588652</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36689610" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">36689610</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Passionflower/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Paxlovid/" title="Next page in this title">Next ></a></div></div></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK588652&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK588652/?report=printable&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal106 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |